Adamas Pharmaceuticals, Inc. (ADMS) Stake Held by Kerrisdale Advisers, LLC

Kerrisdale Advisers, LLC

disclosed that they own 6.5% of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a Schedule 13G disclosure that was filed with the SEC on Wednesday, November 1st. The investor owns 1,473,257 shares of the stock valued at approximately $36,330,518. The reporting parties listed on the disclosure included Kerrisdale Partners Master Fund Ltd, Kerrisdale Advisers, LLC and Sahm Adrangi. The disclosure is available through Edgar at this hyperlink.

A number of other institutional investors have also modified their holdings of ADMS. Wells Fargo & Company MN raised its position in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after acquiring an additional 3,358 shares in the last quarter. Bank of New York Mellon Corp raised its position in Adamas Pharmaceuticals by 2.4% in the first quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock worth $1,152,000 after acquiring an additional 1,563 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in Adamas Pharmaceuticals by 153.3% in the first quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock worth $1,956,000 after acquiring an additional 67,654 shares in the last quarter. American International Group Inc. raised its position in Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after acquiring an additional 682 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Adamas Pharmaceuticals by 10.3% in the first quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock worth $12,537,000 after acquiring an additional 66,825 shares in the last quarter. Hedge funds and other institutional investors own 71.95% of the company’s stock.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) traded up 4.58% during mid-day trading on Wednesday, reaching $25.79. The company’s stock had a trading volume of 3,422,014 shares. The company’s market cap is $580.64 million. Adamas Pharmaceuticals, Inc. has a 12 month low of $12.10 and a 12 month high of $27.87. The stock’s 50 day moving average is $20.77 and its 200 day moving average is $18.00.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. Adamas Pharmaceuticals’s revenue for the quarter was down 90.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.78) earnings per share. Equities research analysts predict that Adamas Pharmaceuticals, Inc. will post ($3.77) EPS for the current year.

Several equities research analysts have commented on ADMS shares. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, August 9th. Cowen and Company set a $45.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Mizuho restated a “buy” rating and set a $26.00 price objective on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a report on Sunday, September 17th. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $39.50.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/11/01/adamas-pharmaceuticals-inc-adms-stake-held-by-kerrisdale-advisers-llc.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

What are top analysts saying about Adamas Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adamas Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit